Ramosetron as a Supportive Agent to Continue Nintedanib in Patients with Interstitial Lung Disease. Satonaga Y, Kudoh R, Hata M, Shigenaga T, et al. Intern Med 2025 Sep 11. doi: 10.2169/internalmedicine.5984.

Read + Share

Amedeo Smart

Independent Medical Education

Satonaga Y, Kudoh R, Hata M, Shigenaga T, et al. Ramosetron as a Supportive Agent to Continue Nintedanib in Patients with Interstitial Lung Disease. Intern Med 2025 Sep 11. doi: 10.2169/internalmedicine.5984.
PMID: 40930829